The clinical value of leukocyte Rho-associated kinases in in catheter ablation of atrial fibrillation

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100042146

Enrollment

Unknown

Registered

2021-01-14

Start date

2021-01-10

Completion date

Unknown

Last updated

2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

Gold Standard:Clinical outcome

Index test:leukocyte&#32

Rho-associated&#32

kinases

Eligibility

Sex/Gender

All

Age

20 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Atrial fibrillation (paroxysmal or persistent), ventricular premature beat, paroxysmal supraventricular tachycardia; 2. Catheter radiofrequency ablation for failure to respond to at least one antiarrhythmic drug.

Exclusion criteria

Exclusion criteria: Valvular heart disease, congenital heart disease, coronary atherosclerotic heart disease, viral myocarditis, cardiomyopathy, peripheral arterial disease, diabetes, chronic hepatic and renal insufficiency, thyroid disease, autoimmune disease, dyslipidemia, pregnancy, craniocerebral injury, tumor, and previous catheter ablation.

Design outcomes

Primary

Measure	Time frame
Rho kinase activity;COX40;recurrence rate of atrial fibrillation;SEN, SPE, ACC, AUC of ROC;	—

Secondary

Measure	Time frame
IL-12;IL-1b;TNF-a;	—

Countries

China

Contacts

Public ContactWenhua Li

Affiliated Wujin Hospital of Jiangsu University,Changzhou

64641233@qq.com+86 13915895326

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026